A Recent Illustration of SomeEssentials of Circadian Chronotherapy Study Design

Journal of Clinical Oncology

Volumn 22, Issue 14, 2004, Pages 2971-2972

  Hrushesky, William ^a   Wood, Patricia ^a   Levi, Francis ^b   Roemeling, Reinhard Von ^c   Bjarnason, Georg ^d   Focan, Christian ^e   Meier, Klaus ^f   Cornélissen, Germaine ^g   Halberg, Franz ^g  

^a Administration Medical Center   (United States)

^b HÔPITAL PAUL BROUSSE   (France)

^c Schering AG Germany   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e Clinique Saint Joseph   (Belgium)

^f LBK Hamburg   (Germany)

^g UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN;

CHRONOTHERAPY; FEMALE; HUMAN; METHODOLOGY; NOTE; OVARY TUMOR;

ANTINEOPLASTIC AGENTS; CHRONOTHERAPY; CISPLATIN; DOXORUBICIN; FEMALE; HUMANS; OVARIAN NEOPLASMS;

EID: 4344585684     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2004.99.042     Document Type: Letter

References (10)

1. Hrushesky W: Circadian timing of cancer chemotherapy. Science 228:73-75, 1985
2. Sothern R, Levi F, Haus E, et al: Control of a murine plasmacytoma with doxorubicin-cisplatin depends upon circadian stage of treatment. J Natl Cancer Inst 81:135-145, 1989
3. Hrushesky W, Bjarnason G: Circadian cancer therapy. J Clin Oncol 11:1403-1417, 1993
4. Levi F, Benavides M, Chevelle C, et al: Chemotherapy of advanced ovarian cancer with 4-0-tetrahydropyranyl doxorubicin and cisplatin: A randomized phase II trial with an evaluation of circadian timing and doseintensity. J Clin Oncol 8:705-714, 1990
5. Barrett RJ, Blessing JA, Homesley HD, et al: Circadian-timed combination doxorubicin-cisplatin chemotherapy for advanced endometrial carcinoma: A phase II study of the Gynecologic Oncology Group. Am J Clin Oncol 16:494-496, 1993
6. Gallion H, Brunetto V, Cibull M, et al: Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: A gynecologic oncology group study. J Clin Oncol 21:3808-3813, 2003
7. Levi F, Zidani R, Vannetzel J, et al: Chronomodulated versus fixedinfusion- rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial. J Natl Cancer Inst 86: 1608-1617, 1994
8. Hrushesky W: Predictable within individual temporal variability and clinical trial design. Presented at Clinical Trials in Oncology: Improving Their Design and Analysis, Toronto, Ontario, Canada, October 28-30, 1993
9. Baron B, Legrand C, Levi F, et al: Chronomodulation: Optimal time finding design. Presented at Society of Clinical Trials Meeting, Denver, CO, May 20-23, 2001
10. Halberg F, Cornélissen G, Wang Z, et al: Chronomics: Circadian and circaseptan timing of radiotherapy, drugs, calories, perhaps nutriceutals and beyond. J Exp Ther Oncol 3:223-260, 2003